The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt Lymphoma
PurposeBurkitt lymphoma (BL) is an invasive lymphoma subtype with FDG avid at 18F-FDG PET/CT, but there is currently no validated criterion in treatment evaluation and prognosis prediction. The aim of this study was to analyze the clinical accuracy of 18F-FDG PET/CT in Burkitt lymphoma in end of the...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.625436/full |
| _version_ | 1819086871154655232 |
|---|---|
| author | Yi Wen Mo Zi Zheng Xiao Yuan Wei Xin Ling Li Xu Zhang Wei Fan |
| author_facet | Yi Wen Mo Zi Zheng Xiao Yuan Wei Xin Ling Li Xu Zhang Wei Fan |
| author_sort | Yi Wen Mo |
| collection | DOAJ |
| description | PurposeBurkitt lymphoma (BL) is an invasive lymphoma subtype with FDG avid at 18F-FDG PET/CT, but there is currently no validated criterion in treatment evaluation and prognosis prediction. The aim of this study was to analyze the clinical accuracy of 18F-FDG PET/CT in Burkitt lymphoma in end of therapy PET/CT (EOT-PET) to assess the treatment response in BL and conduct a survival analysis with different Deauville 5-point score (DS) cutoff values.Materials and MethodsA total of 189 patients were retrospectively included: 97 underwent baseline PET/CT and all underwent EOT-PET. Survival curves were plotted according to the Kaplan-Meier method. Different DS cutoff values in EOT-PET were evaluated for risk stratification in Burkitt lymphoma.ResultsThe median progression free survival (PFS) and overall survival (OS) were 52 and 53 months, respectively. Applying the conventional DS 4 to 5, there was significant difference in outcome between EOT-PET negative and positive patients. However, the positive predictive value (PPV) (28.3% for PFS and 26.4% for OS) is low despite a high negative predictive value (NPV) (94.1% for OS and 94.9% for OS). When we moved the cutoff point to DS 5, the PPV was improved evidently (88.2% for PFS and 82.3% for OS) with the satisfactory NPV simultaneously (95.3% for PFS and 95.9% for OS).ConclusionsEOT-PET results using DS significantly related with PFS and OS. DS of 5 may be a better cutoff point at the end of treatment to determine whether patients have a significant risk of recurrence or progress. |
| first_indexed | 2024-12-21T21:27:08Z |
| format | Article |
| id | doaj.art-d60f9cf8e00e4f2fa86cf92010f15d74 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-21T21:27:08Z |
| publishDate | 2021-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d60f9cf8e00e4f2fa86cf92010f15d742022-12-21T18:49:43ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.625436625436The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt LymphomaYi Wen MoZi Zheng XiaoYuan WeiXin Ling LiXu ZhangWei FanPurposeBurkitt lymphoma (BL) is an invasive lymphoma subtype with FDG avid at 18F-FDG PET/CT, but there is currently no validated criterion in treatment evaluation and prognosis prediction. The aim of this study was to analyze the clinical accuracy of 18F-FDG PET/CT in Burkitt lymphoma in end of therapy PET/CT (EOT-PET) to assess the treatment response in BL and conduct a survival analysis with different Deauville 5-point score (DS) cutoff values.Materials and MethodsA total of 189 patients were retrospectively included: 97 underwent baseline PET/CT and all underwent EOT-PET. Survival curves were plotted according to the Kaplan-Meier method. Different DS cutoff values in EOT-PET were evaluated for risk stratification in Burkitt lymphoma.ResultsThe median progression free survival (PFS) and overall survival (OS) were 52 and 53 months, respectively. Applying the conventional DS 4 to 5, there was significant difference in outcome between EOT-PET negative and positive patients. However, the positive predictive value (PPV) (28.3% for PFS and 26.4% for OS) is low despite a high negative predictive value (NPV) (94.1% for OS and 94.9% for OS). When we moved the cutoff point to DS 5, the PPV was improved evidently (88.2% for PFS and 82.3% for OS) with the satisfactory NPV simultaneously (95.3% for PFS and 95.9% for OS).ConclusionsEOT-PET results using DS significantly related with PFS and OS. DS of 5 may be a better cutoff point at the end of treatment to determine whether patients have a significant risk of recurrence or progress.https://www.frontiersin.org/articles/10.3389/fonc.2021.625436/fullDeauville 5-point scaleBurkitt lymphomaprognosisFDGPET/CT |
| spellingShingle | Yi Wen Mo Zi Zheng Xiao Yuan Wei Xin Ling Li Xu Zhang Wei Fan The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt Lymphoma Frontiers in Oncology Deauville 5-point scale Burkitt lymphoma prognosis FDG PET/CT |
| title | The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt Lymphoma |
| title_full | The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt Lymphoma |
| title_fullStr | The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt Lymphoma |
| title_full_unstemmed | The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt Lymphoma |
| title_short | The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt Lymphoma |
| title_sort | clinical accuracy and risk stratification in end of therapy 18f fdg pet ct in burkitt lymphoma |
| topic | Deauville 5-point scale Burkitt lymphoma prognosis FDG PET/CT |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.625436/full |
| work_keys_str_mv | AT yiwenmo theclinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT zizhengxiao theclinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT yuanwei theclinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT xinlingli theclinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT xuzhang theclinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT weifan theclinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT yiwenmo clinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT zizhengxiao clinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT yuanwei clinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT xinlingli clinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT xuzhang clinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma AT weifan clinicalaccuracyandriskstratificationinendoftherapy18ffdgpetctinburkittlymphoma |